ArticleMolecular medicine (Cambridge, Mass.)2025
Epigenetic reprogramming drives endothelial dysfunction via neuropilin-1 in pulmonary hypertension.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Post-translational modification crosstalk in pulmonary arterial hypertension: mechanisms and therapeutic implications.Molecular biology reports · 2026Review
- Sotatercept Reverses SIN3a Deficiency-Driven PAH by Reprogramming BMPR2/TGF-β-HIF-1α Signaling Pathways.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPulmonary arterial hypertension (PAH) is characterized by progressive vascular remodeling and right ventricular failure. Endothelial dysfunction plays a key role in PAH initiation and progression. Recent studies have implicated epigenetic dysregulation, particularly histone acetylation, as a key contributor to the transcriptional reprogramming underlying PAH. Among the histone acetyltransferases, EP300 catalyzes H3K27 acetylation and modulates transcriptional and metabolic programs in vascular cells. However, its specific role in endothelial dysfunction in PAH remains unclear. METHODS AND
resultsWe investigated the role of EP300 in regulating transcriptional and functional responses in human pulmonary artery endothelial cells (PAECs) in PAH. Human and experimental PAH tissues showed increased EP300 expression and elevated H3K27ac levels. Pharmacological inhibition of EP300 in PAH-derived PAECs reduced global H3K27ac levels, oxidative stress, abnormal proliferation, and inflammatory responses. Transcriptomic analysis revealed that EP300 regulates gene networks related to inflammation, angiogenesis, and metabolism. Among these, neuropilin-1 (NRP1) has emerged as a direct EP300 target marked by H3K27ac enrichment in its regulatory regions. EP300 overexpression up-regulated NRP1 expression, whereas EP300 inhibition decreased NRP1 expression. Functional studies further demonstrated that NRP1 modulates VEGFR2 signaling and glycolytic gene expression. Notably, the pharmacological inhibition of NRP1 with EG00229 attenuated EP300-induced endothelial proliferation and oxidative stress in vitro.
conclusionsOur findings identified EP300 as a central epigenetic regulator of endothelial dysfunction in PAH through H3K27ac-dependent activation of NRP1. The EP300-NRP1 axis integrates inflammatory, angiogenic, and metabolic signaling, contributing to endothelial dysfunction and disease onset. Targeting EP300-mediated histone acetylation may represent a promising therapeutic strategy for restoring endothelial homeostasis and slowing disease progression in patients with PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.